• 1
    Soumerai SB & Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees—a call to action (published erratum appears in N Engl J Med 1999;340:976). N Engl J Med. 1999;340:7228.
  • 2
    Lagnado L. The uncovered; drug costs can leave elderly a grim choice: pills or other needs. Wall Street Journal. November 17, 1998: A1.
  • 3
    Dustan HP, Caplan LR, Curry CL, et al. Report of the Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent. Circulation. 1992;85:84960.
  • 4
    Drazen JM, Bush GW, Gore A. The Republican and Democratic candidates speak on health care. N Engl J Med. 2000;343:11849.
  • 5
    Shih YC. Effect of insurance on prescription drug use by ESRD beneficiaries. Health Care Financ Rev. 1999;20:3954.
  • 6
    Poisal JA & Chulis GS. Medicare beneficiaries and drug coverage. Health Aff. 2000;19:24856.
  • 7
    Poisal JA & Murray L. Growing differences between Medicare beneficiaries with and without drug coverage. Health Aff. 2001;20:7485.
  • 8
    Lillard LA, Rogowski J, Kington R. Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population. Med Care. 1999;37:92636.DOI: 10.1097/00005650-199909000-00008
  • 9
    Department of Health and Human Services. Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices. 2000. Available at:
  • 10
    Soldo BJ, Hurd MD, Rodgers WL, Wallace RB. Asset and health dynamics among the oldest old: an overview of the AHEAD study. J Gerontol B Psychol Sci Soc Sci. 1997;52:120.
  • 11
    Heeringa S. Technical Description of the Asset and Health Dynamics (AHEAD) Survey Sample Design (Public Use Version). Ann Arbor: University of Michigan Institute for Social Research; 1995.
  • 12
    Smith JP. Wealth inequality among older Americans. J Gerontol B Psychol Sci Soc Sci. 1997;52:7481.
  • 13
    Hopp FP & Duffy SA. Racial variations in end-of-life care. J Am Geriatr Soc. 2000;48:65863.
  • 14
    McKinley ED, Garrett JM, Evans AT, Danis M. Differences in end-of-life decision making among black and white ambulatory cancer patients. J Gen Intern Med. 1996;11:6516.
  • 15
    Escarce JJ, Epstein KR, Colby DC, Schwartz JS. Racial differences in the elderly's use of medical procedures and diagnostic tests. Am J Public Health. 1993;83:94854.
  • 16
    Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Aff. 2000;19:21930.
  • 17
    Stuart B & Grana J. Ability to pay and the decision to medicate. Med Care. 1998;36:20211.DOI: 10.1097/00005650-199802000-00009
  • 18
    Stuart B & Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff. 1999;18:20112.
  • 19
    Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35:111931.DOI: 10.1097/00005650-199711000-00004
  • 20
    Tamblyn R, Laprise R, Hanley JA. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:4219.
  • 21
    Lurie N, Ward NB, Shapiro MF, Brook RH. Termination from Medi-Cal—does it affect health? N Engl J Med. 1984;311:4804.
  • 22
    Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317:5506.
  • 23
    Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:10727.
  • 24
    Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:6505.
  • 25
    Schweitzer SO & Shiota SR. Access and cost implications of state limitations on Medicaid reimbursement for pharmaceuticals. Annu Rev Public Health. 1992;13:399410.
  • 26
    Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study (published erratum appears in Circulation 1996;94:849). Circulation. 1996;93:1796802.
  • 27
    Rosenheck R, Cramer J, Allan E, et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry. 1999;56:56572.
  • 28
    Gross DJ, Alecxih L, Gibson MJ, Corea J, Caplan C, Brangan N. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries. Health Serv Res. 1999;34:24154.
  • 29
    Rogowski J, Lillard LA, Kington R. The financial burden of prescription drug use among elderly persons. Gerontologist. 1997;37:47582.
  • 30
    Stuart B, Shea D, Briesacher B. Dynamics of drug coverage of Medicare beneficiaires: finders, losers, switchers. Health Aff. 2001;20:8699.
  • 31
    McArdle F, Cappock S, Yamamoto D, Zebrak A. Retiree Health Coverage: Recent Trends and Employer Perspectives on Future Benefits. Menlo Park, Calif: The Henry J. Kaiser Family Foundation; 1999.
  • 32
    Sjahid SI, Van Der Linden PD, Stricker BH. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam Elderly Study. Br J Clin Pharmacol. 1998;45:5915.
  • 33
    Rost K & Roter D. Predictors of recall of medication regimens and recommendations for lifestyle change in elderly patients. Gerontologist. 1987;27:5105.
  • 34
    West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:110312.
  • 35
    McKenna MT, Speers M, Mallin K, Warnecke R. Agreement between patient self-reports and medical records for Pap smear histories. Am J Prev Med. 1992;8:28791.
  • 36
    Brown JB & Adams ME. Patients as reliable reporters of medical care process. Recall of ambulatory encounter events. Med Care. 1992;30:40011.
  • 37
    Evans C & Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics. 1999;15:24156.
  • 38
    Coughlin SS. Recall bias in epidemiologic studies. J Clin Epidemiol. 1990;43:8791.
  • 39
    Norrish A, North D, Kirkman P, Jackson R. Validity of self-reported hospital admission in a prospective study. Am J Epidemiol. 1994;140:93842.
  • 40
    Yaffe R, Shapiro S, Fuchseberg RR, Rohde CA, Corpeno HC. Medical economics survey-methods study: cost-effectiveness of alternative survey strategies. Med Care. 1978;16:64159.
  • 41
    Cleary PD & Jette AM. The validity of self-reported physician utilization measures. Med Care. 1984;22:796803.
  • 42
    McCall N, Rice T, Sangl J. Consumer knowledge of Medicare and supplemental health insurance benefits. Health Serv Res. 1986;20:63357.